ABM Reagents

<h2 dir="ltr">What Are AAV and Adenovirus CRISPR Delivery Systems?</h2>
 AAV and adenovirus-based delivery systems exploit the natural cell-entry machinery of these viruses to deliver Cas9 and guide RNA cargo into cells that resist conventional transfection &mdash; including primary cells, stem cells, neurons, and in vivo tissues. AAV is the most widely used viral vector for CRISPR-based gene editing, valued for high transduction efficiency, low immunogenicity, and an established safety profile in human gene therapy. The right viral delivery system influences transduction efficiency, expression profile, and genome-editing outcomes. AAV and adenoviral vectors offer distinct advantages depending on your research goals.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li data-section-id="17k5oh4" data-start="0" data-end="142">Adenoviral Cas9 &amp; Nickase Nucleases: Viral delivery systems for rapid, transient Cas9 or nickase expression without genomic integration.</li>
<li data-section-id="12kolej" data-start="144" data-end="280">AAV6 &amp; AAV8 Viral Vectors: Serotype-specific AAV vectors optimized for transduction of hematopoietic stem cells and liver tissues.</li>
<li data-section-id="81toc4" data-start="282" data-end="412">saCas9 AAV Serotypes (1&ndash;10): Diverse AAV serotypes designed to support targeted cellular tropism across CRISPR applications.</li>
<li data-section-id="18h5j1a" data-start="414" data-end="554">Ampicillin-Selected AAV Vectors: AAV vector backbones containing ampicillin resistance markers for cloning and transformant selection.</li>
<li data-section-id="xfx9g1" data-start="556" data-end="697" data-is-last-node="">High-Titer Viral Particles: Purified viral preparations optimized to maintain genomic integrity and minimize endotoxin-related effects.</li>
</ul>
<h2 dir="ltr"> How to Choose AAV/Adenovirus CRISPR Delivery</h2>
 Genome Capacity Requirements AAV's ~4.7 kb packaging capacity is too small for full-length SpCas9 (~4.2 kb) plus a promoter and guide RNA. Split-vector systems (Cas9 across two AAV particles) or compact Cas9 orthologs such as SaCas9 (~3.2 kb) address this limit. Adenovirus offers 34&ndash;43 kb capacity for larger cargo. Serotype and Tissue Tropism AAV serotypes differ in their ability to transduce specific cell types and tissues, making serotype selection an important part of CRISPR delivery design. The optimal serotype depends on the target tissue, model system, administration route, and experimental goals. MBP offers saCas9 AAV viruses in multiple serotypes (AAV1&ndash;AAV11) to support a range of research applications. Cell Division Status Both AAV and adenovirus transduce dividing and non-dividing cells, making them suitable for primary neurons, hepatocytes, and other post-mitotic populations that resist standard transfection. Immunogenicity Considerations AAV has low immunogenicity and minimal integration risk, supporting widespread pre-clinical and clinical in vivo use. Adenovirus offers higher initial transduction efficiency and larger cargo capacity but generates a stronger immune response, which can limit in vivo utility. Packaging System Helper-free packaging systems eliminate the need for replication-competent helper virus, designed for BSL-2 containment &mdash; though institutional biosafety committee (IBC) approval is required before starting viral vector work. 
<h2 dir="ltr"> Specifications Context</h2>
 AAV and adenoviral CRISPR delivery systems support retinal gene therapy models, CNS editing studies, liver-targeted in vivo CRISPR, muscle cell engineering, primary immune cell editing, iPSC-derived cell modification, and genome-modified animal model generation. Capsid engineering through directed-evolution platforms continues to expand AAV tropism options, including enhanced CNS penetration following systemic delivery, an active area of pre-clinical research relevant to labs planning long-term in vivo programs. All recombinant AAV production and adenoviral vector work requires IBC approval at BSL-2 containment in most jurisdictions; MBP can provide biosafety classification documentation. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
Reach out to the professional <a href="https://mbpinc.net/contact-us" style="color: #236fa1; text-decoration: underline;">team at MBP Inc</a>. now to ask for a quote for a suitable AAV or Adenovirus system for your lab.

AAV/Adenovirus Systems

saCas9 Nuclease AAV Vector with ampicillin

K207 by Applied Biological Materials is an AAV transfer plasmid (10 µg, ampicillin resistance) encoding S. aureus Cas9 (saCas9; ~1 kb smaller than spCas9; NNGRRT PAM) for producing custom saCas9-AAV particles. Package with the appropriate serotype-specific AAV packaging mix. Pre-packaged saCas9 AAV viruses available: AAV3 (K210), AAV6 (K213), AAV8 (K215). Separate saCas9 sgRNA required. Store at &minus;20°C.

Unit Quantity

Vector

Shipping Condition

saCas9 Nuclease AAV Virus (AAV1)

K208 saCas9 Nuclease AAV Virus (AAV1) by Applied Biological Materials delivers S. aureus Cas9 (~1 kb smaller than SpCas9) via AAV serotype 1 for CRISPR gene editing with the 5&prime;-NNGRRT-3&prime; PAM. Supplied at 1011 GC/mL as 5 &times; 100 µl; store at &minus;80&deg;C.

Titer

Storage Condition

saCas9 Nuclease AAV Virus (AAV10)

K217 saCas9 Nuclease AAV Virus (AAV10) by Applied Biological Materials delivers S. aureus Cas9 (~1 kb smaller than SpCas9) via AAV serotype 10 for in vivo and post-mitotic CRISPR gene editing with the 5&prime;-NNGRRT-3&prime; PAM. Supplied at 1011 GC/mL as 5 &times; 100 µl; store at &minus;80&deg;C.

saCas9 Nuclease AAV Virus (AAV11)

K218 saCas9 Nuclease AAV Virus (AAV11) by Applied Biological Materials delivers S. aureus Cas9 via AAV serotype 11 for in vivo CRISPR editing with the 5&prime;-NNGRRT-3&prime; PAM, providing an alternative capsid for tissues or models with pre-existing immunity to common AAV serotypes. 1011 GC/mL; 5 &times; 100 µl; store at &minus;80&deg;C.

saCas9 Nuclease AAV Virus (AAV2)

K209 saCas9 Nuclease AAV Virus (AAV2) by Applied Biological Materials delivers S. aureus Cas9 via AAV serotype 2 (HSPG receptor; broad neuronal, retinal, and hepatocyte tropism) for in vivo CRISPR editing with the 5&prime;-NNGRRT-3&prime; PAM. 1011 GC/mL; 5 &times; 100 µl; store at &minus;80&deg;C.

saCas9 Nuclease AAV Virus (AAV3)

K210 by Applied Biological Materials is a pre-packaged AAV3 virus expressing S. aureus Cas9 (saCas9) at 1011 GC/ml (5 × 100 µl). saCas9 is ~1 kb smaller than spCas9; uses 5'-NNGRRT PAM. AAV3 tropism for hepatocytes (FGFR2) and hematopoietic progenitors. Separate saCas9-compatible sgRNA required. Store at &minus;80°C; single-use aliquots.

saCas9 Nuclease AAV Virus (AAV4)

K211 is saCas9 nuclease packaged in AAV serotype 4 (AAV4), supplied as 3 × 100 µL. saCas9's compact ~3.2 kb coding sequence enables single-vector AAV co-packaging of Cas9 and sgRNA. NNGRRT PAM recognition; designed for in vivo and primary cell CRISPR gene editing via AAV4 delivery. Store at −80°C.

saCas9 Nuclease AAV Virus (AAV5)

K212 saCas9 Nuclease AAV Virus (AAV5) by Applied Biological Materials delivers S. aureus Cas9 (~1 kb smaller than SpCas9) via AAV serotype 5 for in vivo CRISPR gene editing with the 5&prime;-NNGRRT-3&prime; PAM. AAV5 provides broad CNS and airway tropism. 1011 GC/mL; 5 &times; 100 µl; store at &minus;80&deg;C.

saCas9 Nuclease AAV Virus (AAV6)

K213 by Applied Biological Materials is a pre-packaged AAV6 virus expressing S. aureus Cas9 (saCas9) at 1011 GC/ml (5 &times; 100 &micro;l). saCas9 is ~1 kb smaller than spCas9, improving AAV packaging efficiency, and uses a 5'-NNGRRT PAM for greater specificity. AAV6 tropism for hematopoietic stem cells and muscle. Store at &minus;80&deg;C; single-use aliquots.

saCas9 Nuclease AAV Virus (AAV7)

K214 saCas9 Nuclease AAV Virus (AAV7) by Applied Biological Materials delivers S. aureus Cas9 (~1 kb smaller than SpCas9) via AAV serotype 7 for in vivo CRISPR gene editing with the 5&prime;-NNGRRT-3&prime; PAM. AAV7 provides efficient skeletal muscle and liver tropism. 1011 GC/mL; 5 &times; 100 µl; store at &minus;80&deg;C.

saCas9 Nuclease AAV Virus (AAV8)

K215 by Applied Biological Materials is a pre-packaged AAV8 virus expressing S. aureus Cas9 (saCas9) at 1011 GC/ml (5 &times; 100 &micro;l). saCas9 is ~1 kb smaller than spCas9 and uses 5'-NNGRRT PAM. AAV8 provides strong hepatotropism (systemic IV) and muscle transduction. Separate saCas9-compatible sgRNA required. Store at &minus;80&deg;C; single-use aliquots.

saCas9 Nuclease AAV Virus (AAV9)

K216 saCas9 Nuclease AAV Virus (AAV9) by Applied Biological Materials delivers S. aureus Cas9 (~1 kb smaller than SpCas9) via AAV serotype 9 for in vivo CRISPR editing with the 5&prime;-NNGRRT-3&prime; PAM. AAV9 provides broad CNS and cardiac tropism and efficient blood-brain barrier crossing. 1011 GC/mL; 5 &times; 100 µl; store at &minus;80&deg;C.